Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060560 | 0.92 | SIGMAR1 (0.40) | SIGMAR1HRH3 | |
| SCHEMBL28981555 | 0.86 | ALOX15 (0.44) | SIGMAR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL7394145 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HRH3ALOX15 | |
| SCHEMBL2231151 | 0.82 | PIM1 (0.42) | SIGMAR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1186740 | 0.82 | — | — | |
| SCHEMBL4541384 | 0.77 | SIGMAR1 (0.40) | SIGMAR1HRH3 | |
| SCHEMBL9927905 | 0.77 | — | — | |
| SCHEMBL3671614 | 0.77 | SIGMAR1 (0.46) | SIGMAR1HRH3 | |
| SCHEMBL15473873 | 0.76 | MAOA (0.46) | SIGMAR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL24891390 | 0.75 | HRH3 (0.48) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153665-B | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2021-10-15 | — | — | CN | claimed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | claimed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | claimed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | claimed |
| EP-3423446-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-09 | — | — | EP | claimed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | claimed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | claimed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | claimed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | claimed |
| CN-109153665-B | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | disclosed |
| EP-3423446-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101198590-A | Novel pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD (JP) | 2008-06-11 | — | — | CN | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | SIGMAR1 958/4885KDM4E 4584/4885ALDH1A1 2069/4885 |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | SIGMAR1 1729/4885KDM4E 1112/4885ALDH1A1 1243/4885 |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | CYP11B2, CYP19A1, CYP11B1 | SIGMAR1 813/4885KDM4E 2988/4885ALDH1A1 433/4885 |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | SIGMAR1 4435/4885KDM4E 3719/4885ALDH1A1 1208/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | SIGMAR1 105/4885KDM4E 4252/4885ALDH1A1 899/4885 |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | CYP11B2, CYP19A1, CYP11B1 | SIGMAR1 708/4885KDM4E 3175/4885ALDH1A1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.